We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+33.33%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.76B
AUM Growth
+$349M
Cap. Flow
+$63.3M
Cap. Flow %
3.6%
Top 10 Hldgs %
46.56%
Holding
242
New
48
Increased
31
Reduced
35
Closed
71

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$45.5M
2
RDUS
Radius Health, Inc.
RDUS
+$27.1M
3
EVH icon
Evolent Health
EVH
+$21.8M
4
LJPC
La Jolla Pharmaceutical Company
LJPC
+$20.9M
5
ANAB icon
AnaptysBio
ANAB
+$20.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$72.8M
2
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$39.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$30.9M
4
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$23.3M
5
ACOR
Acorda Therapeutics
ACOR
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Miscellaneous 1.35%
3 Consumer Staples 0.26%
4 Consumer Discretionary 0.06%
5 Industrials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTNT
26
DELISTED
Quotient Limited Ordinary Shares
QTNT
$20.4M 1.16%
72,945
+1,583
+2% +$404K
NVRO
27
DELISTED
NEVRO CORP.
NVRO
$20.4M 1.16%
+217,292
New +$19.7M
KDMN
28
DELISTED
Kadmon Holdings, Inc.
KDMN
$18.8M 1.07%
5,185,847
+2,976,190
+135% +$12M
BPMC
29
DELISTED
Blueprint Medicines
BPMC
$18.5M 1.05%
461,642
+187,822
+69% +$6.73M
WVE icon
30
Wave Life Sciences
WVE
$879M
$18.3M 1.04%
665,198
– –
XLRN
31
DELISTED
Acceleron Pharma
XLRN
$17.6M 1%
663,857
+43,870
+7% +$1.16M
TLPH icon
32
Talphera
TLPH
$61.8M
$17M 0.97%
270,436
– –
ASMB icon
33
Assembly Biosciences
ASMB
$532M
$16.9M 0.96%
55,363
-4,167
-7% -$1.02M
AVDL
34
DELISTED
Avadel Pharmaceuticals
AVDL
$13.6M 0.78%
1,408,240
+20,000
+1% +$200K
ALDX icon
35
Aldeyra Therapeutics
ALDX
$82.6M
$12.9M 0.73%
2,885,458
+945,000
+49% +$4.87M
AMAG
36
DELISTED
AMAG Pharmaceuticals
AMAG
$12.6M 0.72%
560,000
+540,476
+2,768% +$12.9M
ANIP icon
37
ANI Pharmaceuticals
ANIP
$1.66B
$12.6M 0.72%
254,889
-12,211
-5% -$686K
CORI
38
DELISTED
Corium International, Inc.
CORI
$11.1M 0.63%
+2,654,485
New +$9.74M
ABMD
39
DELISTED
Abiomed Inc
ABMD
$10.6M 0.61%
85,000
+84,891
+77,882% +$9.84M
CRBP icon
40
Corbus Pharmaceuticals
CRBP
$134M
$10.3M 0.59%
41,667
– –
IRTC icon
41
iRhythm Holdings
IRTC
$3.69B
$10.2M 0.58%
271,057
-81,184
-23% -$2.79M
CLVS
42
DELISTED
Clovis Oncology, Inc.
CLVS
$10M 0.57%
157,754
-10,000
-6% -$608K
BIO icon
43
Bio-Rad Laboratories Class A
BIO
$10.1B
$9.85M 0.56%
49,416
+25,000
+102% +$4.82M
EXAS
44
DELISTED
Exact Sciences
EXAS
$9.68M 0.55%
+410,000
New +$8.12M
ATRS
45
DELISTED
Antares Pharma, Inc.
ATRS
$8.29M 0.47%
2,917,253
– –
MYOK
46
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$8.21M 0.47%
624,694
– –
SNDA icon
47
Sonida Senior Living
SNDA
$1.91B
$8.09M 0.46%
38,345
+17,000
+80% +$4.04M
ALDR
48
DELISTED
Alder Biopharmaceuticals
ALDR
$7.99M 0.46%
384,169
– –
FWP
49
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$7.63M 0.43%
50,606
-5,714
-10% -$1.08M
QURE icon
50
uniQure
QURE
$2.99B
$7.32M 0.42%
1,265,963
– –
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGA
K5 Global Advisor Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q1 2017 Portfolio in Review

As of Q1 2017, Perceptive Advisors held 242 positions worth $1.76B, up 25% from $1.41B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $63.3M of net new capital in Q1 2017, opening 48 new positions and adding to 31 existing holdings. Its largest new stake was AnaptysBio: 881,957 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Consumer Staples.

On the sell side, the largest reduction was TESARO, Inc., an estimated $72.8M trimmed.

  • Perceptive Advisors's largest Q1 2017 buy was AnaptysBio: 881,957 shares worth $24.5M.
  • Perceptive Advisors added most to Alnylam Pharmaceuticals in Q1 2017, an estimated $45.5M increase.
  • Perceptive Advisors's biggest Q1 2017 reduction was TESARO, Inc., cutting an estimated $72.8M.
  • Perceptive Advisors fully exited Eagle Pharmaceuticals, Inc. in Q1 2017, selling an estimated $39.5M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.76B portfolio in Q1 2017.
  • Perceptive Advisors opened 48 new positions and closed 71 in Q1 2017.
  • Perceptive Advisors's portfolio value rose 25% quarter-over-quarter to $1.76B.

Based on Perceptive Advisors's 13F filing for Q1 2017, filed 15 May 2017.